History

Company

About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.

2014

NovHanmi new RFID reader, grand prize for national excellence patent award
Phase 1 clinical trial of HM95573,a next-generation targeted therapy for melanoma treatment
OctBeijing Hanmi, received 'Presidential Prize' at 2014 Korea well-respected corporate awards
Received 'Minister Prize of Health and Welfare' at Sharing Korea awards
SepDiabetes-obesity biologics, presented at EASD
AugLicense agreement with Luye pharma group for targeted anti-cancer dug 'Poziotinib' in China
Diabetes biologic, '^LAPS efpeglenatide', completed patient recruitment in phase IIb clinical trial
JulContract with Actavis for exporting a hyaluronic acid injection
Hanmi opened the official blog 'Saranghanmida'
Hanmi-Novartis, diabetes treatment 'Galvus' co-promotion
JunTriaxone, obtained market authorization in 4 EU countries
sup>LAPSInsulin, weekly diabetes drug, presented at ADA
Rheumatoid arthritis drug, HM71224, presented at EULAR
The 8th Hanmi mid-small hospital award, Seungwon Hong, Director of Daejeon Christian General Hosipital
Plant in Pyeongtaek awarded for joining PIC/S by Korea Food & Drug Administration
May Diabetes-obesity new drug (^LAPS-GLP-1/GCG) enters into global phase 1
Apr Probiotics for kids in Beijing Hanmi, 'Mamiai' is registered as China Famous Trade Mark
Decided to build an extension of BioPlant in Pyeongtaek
Received 'fair trade corporation' award by Fair Trade Commission
Launched Fluterol, DPI type asthma treatment drug
Mar 4th shareholders meeting of Hanmi Pharmaceuticals / 41st shareholders meeting of Hanmi Science
License agreement with Access Pharmaceuticals for Korean commercialization of 'Mugard'
Feb Hanmi-MSD, mutual co-promotion agreement for the sales of 12 products
Succeeded in seasoned equity offering (1 million shares)
Jan Hit 100 billion won in research and development as the first listed pharmaceutical company
Only one in the pharmaceutical industry to receive CP certificate(BBB grade)